777 related articles for article (PubMed ID: 30058393)
1. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
Collins JM; Redman JM; Gulley JL
Expert Rev Vaccines; 2018 Aug; 17(8):697-705. PubMed ID: 30058393
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
Wilky BA
Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
[TBL] [Abstract][Full Text] [Related]
3. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
4. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
5. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
6. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
7. Combination therapies utilizing neoepitope-targeted vaccines.
Lee KL; Schlom J; Hamilton DH
Cancer Immunol Immunother; 2021 Apr; 70(4):875-885. PubMed ID: 33033852
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.
Kon E; Benhar I
Drug Resist Updat; 2019 Jul; 45():13-29. PubMed ID: 31382144
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
10. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.
Gatti-Mays ME; Redman JM; Collins JM; Bilusic M
Hum Vaccin Immunother; 2017 Nov; 13(11):2561-2574. PubMed ID: 28857666
[TBL] [Abstract][Full Text] [Related]
11. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral Immunotherapy: From Trial Design to Clinical Practice.
Champiat S; Tselikas L; Farhane S; Raoult T; Texier M; Lanoy E; Massard C; Robert C; Ammari S; De Baère T; Marabelle A
Clin Cancer Res; 2021 Feb; 27(3):665-679. PubMed ID: 32943460
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic cancer vaccine: building the future from lessons of the past.
Tran T; Blanc C; Granier C; Saldmann A; Tanchot C; Tartour E
Semin Immunopathol; 2019 Jan; 41(1):69-85. PubMed ID: 29978248
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
[TBL] [Abstract][Full Text] [Related]
15. Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer.
Kerr MD; McBride DA; Chumber AK; Shah NJ
Expert Opin Drug Discov; 2021 Jan; 16(1):89-99. PubMed ID: 32867561
[TBL] [Abstract][Full Text] [Related]
16. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
[TBL] [Abstract][Full Text] [Related]
17. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
18. Drug Delivery for Cancer Immunotherapy and Vaccines.
Batty CJ; Tiet P; Bachelder EM; Ainslie KM
Pharm Nanotechnol; 2018; 6(4):232-244. PubMed ID: 30227827
[TBL] [Abstract][Full Text] [Related]
19. Selecting immuno-oncology-based drug combinations - what should we be considering?
Festino L; Vanella V; Trojaniello C; Ascierto PA
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):971-985. PubMed ID: 30169990
[TBL] [Abstract][Full Text] [Related]
20. Methods for improving the immunogenicity and efficacy of cancer vaccines.
Pilla L; Ferrone S; Maccalli C
Expert Opin Biol Ther; 2018 Jul; 18(7):765-784. PubMed ID: 29874943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
